title: Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.
abstract: OBJECTIVE
  Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor.
  
  
  METHODS
  The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later.
  
  
  CONCLUSIONS
  Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.
authors.affiliation: Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
authors.forename: G
authors.initials: G
authors.lastname: Tournaire
authors.affiliation: Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
authors.forename: F
authors.initials: F
authors.lastname: Despas
authors.affiliation: Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France.
authors.forename: F
authors.initials: F
authors.lastname: Huguet
authors.affiliation: Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Montastruc
authors.affiliation: Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
authors.forename: E
authors.initials: E
authors.lastname: Bondon-Guitton
keywords: adverse drug reactions; protein kinase inhibitors; risk factors; vasculopathies